Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2

The coronavirus disease outbreak has caused millions of deaths and widespread unemployment globally. Vaccination boosts neutralizing antibody titers and reduce the spread of SARS-CoV-2 virus. Neutralizing antibodies inhibit the interaction of the virus by blocking the binding between the receptor bi...

Full description

Saved in:
Bibliographic Details
Main Author: Salleh, Faraazlin
Format: Thesis
Language:en
Published: 2023
Subjects:
Online Access:http://eprints.usm.my/60247/1/FARAAZLIN-E.pdf
http://eprints.usm.my/60247/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1834507305374187520
author Salleh, Faraazlin
author_facet Salleh, Faraazlin
author_sort Salleh, Faraazlin
building Hamzah Sendut Library
collection Institutional Repository
content_provider Universiti Sains Malaysia
content_source USM Institutional Repository
continent Asia
country Malaysia
description The coronavirus disease outbreak has caused millions of deaths and widespread unemployment globally. Vaccination boosts neutralizing antibody titers and reduce the spread of SARS-CoV-2 virus. Neutralizing antibodies inhibit the interaction of the virus by blocking the binding between the receptor binding domain of SARS-CoV-2 and the host receptor surface. The primary aim of this study was to evaluate GenScript cPass and ImmuSAFE COVID+ assays for detecting neutralizing antibody titers using samples collected from second and booster doses of the BNT162b2 vaccine. GenScript cPass and ImmuSAFE COVID+ assays are the current neutralization tests on the market. The evaluation of neutralization tests demonstrated a statistically significant increase in neutralizing antibodies after the booster dose using GenScript cPass. In contrast, ImmuSAFE COVID+ showed a decline in neutralizing antibodies after the booster dose. The demographic data between age and gender against neutralizing antibody titers was also evaluated, showing no correlation between gender and age towards neutralizing antibodies. The study concludes that GenScript cPass and ImmuSAFE COVID+ assays demonstrate the ability in determining neutralizing antibody titers post-vaccination.
format Thesis
id my.usm.eprints.60247
institution Universiti Sains Malaysia
language en
publishDate 2023
record_format eprints
spelling my.usm.eprints.60247 http://eprints.usm.my/60247/ Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2 Salleh, Faraazlin R Medicine RC109-216 Infectious and parasitic diseases The coronavirus disease outbreak has caused millions of deaths and widespread unemployment globally. Vaccination boosts neutralizing antibody titers and reduce the spread of SARS-CoV-2 virus. Neutralizing antibodies inhibit the interaction of the virus by blocking the binding between the receptor binding domain of SARS-CoV-2 and the host receptor surface. The primary aim of this study was to evaluate GenScript cPass and ImmuSAFE COVID+ assays for detecting neutralizing antibody titers using samples collected from second and booster doses of the BNT162b2 vaccine. GenScript cPass and ImmuSAFE COVID+ assays are the current neutralization tests on the market. The evaluation of neutralization tests demonstrated a statistically significant increase in neutralizing antibodies after the booster dose using GenScript cPass. In contrast, ImmuSAFE COVID+ showed a decline in neutralizing antibodies after the booster dose. The demographic data between age and gender against neutralizing antibody titers was also evaluated, showing no correlation between gender and age towards neutralizing antibodies. The study concludes that GenScript cPass and ImmuSAFE COVID+ assays demonstrate the ability in determining neutralizing antibody titers post-vaccination. 2023-08 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/60247/1/FARAAZLIN-E.pdf Salleh, Faraazlin (2023) Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2. Masters thesis, Universiti Sains Malaysia.
spellingShingle R Medicine
RC109-216 Infectious and parasitic diseases
Salleh, Faraazlin
Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_full Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_fullStr Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_full_unstemmed Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_short Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_sort evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of bnt162b2
topic R Medicine
RC109-216 Infectious and parasitic diseases
url http://eprints.usm.my/60247/1/FARAAZLIN-E.pdf
http://eprints.usm.my/60247/
url_provider http://eprints.usm.my/